MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by EL-FAKAHANY, E.
Right arrow Articles by RICHELSON, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by EL-FAKAHANY, E.
Right arrow Articles by RICHELSON, E.

Molecular Pharmacology, Vol 20, 519-525, Copyright © 1981 by the American Society for Pharmacology and Experimental Therapeutics

Phenoxybenzamine and Dibenamine Interactions with Calcium Channel Effectors of the Muscarinic Receptor

ESAM EL-FAKAHANY 1 and ELLIOTT RICHELSON 1

1 Departments of Psychiatry and Pharmacology, Mayo Foundation, Rochester, Minnesota 55905

Phenoxybenzamine and dibenamine were more effective at blocking muscarinic acetylcholine receptor-mediated cyclic GMP formation in mouse neuroblastoma cells (clone N1E-115) than at blocking radiolabeled antagonist binding to the muscarinic receptors of these cells. High calcium concentrations antagonized the effects of these 2-halogenoethylamines on the cyclic GMP response but not on the receptor binding. In addition, the apparent equilibrium dissociation constant for carbachol and the muscarinic receptor determined in the biological assay with the use of the 2-halogenoethylamines was several-fold greater than that determined by radioligand binding assays. These results suggest that phenoxybenzamine and dibenamine interact with calcium channels in addition to muscarinic receptors, and on the basis of these and other results, we propose a scheme for the interactions of agonists and antagonists with muscarinic receptors and their effectors (calcium channels).

Submitted on October 28, 1980
Accepted on June 29, 1981







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1981 by the American Society for Pharmacology and Experimental Therapeutics